ArticleInternational journal of women's health2025
GnRH-a Pretreatment Doses and Frozen-Thawed Blastocyst Transfer Outcomes in PCOS Patients: A Retrospective Cohort Study.
Article in International journal of women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the effects of GnRH-a pretreatment with 1.5 mg or 3.75 mg, in combination with hormone replacement therapy (HRT), on pregnancy outcomes in women with polycystic ovary syndrome (PCOS) undergoing frozen embryo transfer (FET). Methods: We conducted a retrospective analysis of 555 FET cycles in PCOS patients treated at our center between July 2022 and June 2024. Based on endometrial preparation regimens, participants were allocated into three groups: HRT alone, GnRH-a (1.5 mg) + HRT, and GnRH-a (3.75 mg) + HRT. Baseline characteristics and pregnancy outcomes were compared among the groups. Multivariable logistic regression was used to adjust for potential confounders. Results: Baseline characteristics were comparable among groups in age, duration of infertility, body mass index (BMI), endometrial thickness on the start day, estradiol (E2) and luteinizing hormone (LH) on the start day, endometrial thickness on the day of embryo transfer (ET), E2 on the ET day, and days of estradiol valerate administration (all P > 0.05). The proportion of double-embryo transfer cycles was higher in the 1.5 mg GnRH-a + HRT group than in the other two groups (P < 0.001). Pregnancy outcomes, including implantation rate (54.17% vs 46.81% vs 56.73%), clinical pregnancy rate (57.68% vs 57.43% vs 63.70%), early pregnancy loss rate (11.41% vs 13.24% vs 9.30%), and ectopic pregnancy rate (1.09% vs 0.00% vs 1.16%), did not differ significantly among groups (P > 0.05). Multivariable analysis identified the number of embryos transferred as the only factor significantly associated with pregnancy outcome (P < 0.001). Conclusion: GnRH-a pretreatment at either 1.5 mg or 3.75 mg did not confer a clear benefit over HRT alone in PCOS patients undergoing FET. The number of embryos transferred remains the primary determinant of pregnancy outcome. Larger prospective studies are warranted to validate these findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.